Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.47 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.47 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.47 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6109703 | 0.93 | MAPT (0.81) | MAPTSMN1; SMN2LMNAHTTTP53 | |
| SCHEMBL28405115 | 0.85 | MAPT (0.65) | MAPTSMN1; SMN2LMNAHTTTP53 | |
| SCHEMBL3919214 | 0.85 | TUBB1 (0.56) | MAPTSMN1; SMN2LMNAHTTTP53 | |
| SCHEMBL20355378 | 0.82 | MAPT (0.55) | MAPTSMN1; SMN2LMNAHTTTP53 | |
| SCHEMBL5784803 | 0.80 | MAPT (0.78) | MAPTSMN1; SMN2LMNAHTTTP53 | |
| SCHEMBL28316621 | 0.74 | PRKAB2 (0.51) | MAPTKDM4EALDH1A1CDK4CCND1 | |
| SCHEMBL7083892 | 0.74 | MAPT (0.67) | MAPTSMN1; SMN2LMNAHTTTP53 | |
| SCHEMBL5971912 | 0.73 | MAPT (0.66) | MAPTSMN1; SMN2LMNAHTTTP53 | |
| SCHEMBL7089708 | 0.73 | MAPT (0.63) | MAPTSMN1; SMN2LMNAHTTTP53 | |
| SCHEMBL7090097 | 0.73 | MAPT (0.66) | MAPTSMN1; SMN2LMNAHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833787-A2 | INDOLE DERIVATIVES FOR USE AS PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20060135540-A1 | PPAR active compounds | PLEXXIKON, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006060535-A2 | INDOLE DERIVATIVES FOR USE AS PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135540-A1 | PPAR active compounds | PPARG, PPARA, PPARD | MAPT 4530/4885SMN1; SMN2 4614/4885LMNA 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.